# Natera (NTRA) — News

NTRA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ntra/news

## Recent headlines

- [ABSA names NCBA's Muriuiki to role in personal banking unit: BD](https://www.ainvest.com/news/absa-names-ncba-muriuiki-role-personal-banking-unit-bd-2610) — AInvest Wire, Oct 14, 2026
- [Natera & Transcode Therapeutics collaborate on CRC](https://www.ainvest.com/news/natera-transcode-therapeutics-collaborate-crc-2610) — AInvest Wire, Oct 13, 2026
  Natera, Inc. (NASDAQ: NTRA) has announced a collaboration with Transcode Therapeutics to advance research and development in the detection and treatment of colorectal cancer (CRC). The partnership aims to leverage Natera’s expertise in genomic analysis and Transcode’s innovative therapeutic…
- [Natera - Transcode to use Signatera test to identify mrd-positive patients for enrollment](https://www.ainvest.com/news/natera-transcode-signatera-test-identify-mrd-positive-patients-enrollment-2610) — AInvest Wire, Oct 13, 2026
- [Natera and Transcode Therapeutics to collaborate on phase 2A trial of TTX-MC138 in colorectal cancer](https://www.ainvest.com/news/natera-transcode-therapeutics-collaborate-phase-2a-trial-ttx-mc138-colorectal-cancer-2610) — AInvest Wire, Oct 13, 2026
  Natera, Inc. (NASDAQ: NTRA) and Transcode Therapeutics have announced a collaboration to conduct a phase 2A clinical trial of TTX-MC138, an investigational therapy targeting colorectal cancer. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of TTX-MC138 in patients…
- [Natera, Inc.: TD Cowen raises target price to $480 from $340](https://www.ainvest.com/news/natera-td-cowen-raises-target-price-480-340-2610) — AInvest Wire, Oct 13, 2026
  TD Cowen has raised its price target for Natera, Inc. (NASDAQ: NTRA) to $480 from $340, reflecting a significant increase in analyst optimism regarding the company’s future performance. Natera, a leader in cell-free DNA (cfDNA) and genetic testing, operates across oncology, women’s health, and…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).